Class IIITerminated in FDA datasetRecall initiated Aug 6, 2025

Hi-Tech Pharmaceuticals Slimaglutide Revolutionary Weight Loss Aid With Glucagon-Like Peptide-1…

Recalling firm: Hi-Tech Pharmaceuticals Inc.

Why it was recalled

Unapproved Drug Claims and Misbranded.

Historical recall record. This is not a new recall announcement. “Terminated” describes the FDA recall process; it does not certify that an individual package is safe. FDA termination date: Feb 19, 2026.

Check your package

Compare the exact product and package details with the label you have.

ProductHI-TECH PHARMACEUTICALS SLIMAGLUTIDE REVOLUTIONARY WEIGHT LOSS AID WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONIST AND SECRETAGOGUES NOVEL GIP (GLUCOSE-DEPENDENT ISNULINOTROPIC POLYPEPTIDE) RECEPTOR AGONIST 180 TABLETS DIETARY SUPPLEMENT

FDA code information

Lot C19El8 Exp Date 05/30

Match the product, package size, and code together. A missing match does not guarantee safety.

Full FDA record and distribution details

Original product description

HI-TECH PHARMACEUTICALS SLIMAGLUTIDE REVOLUTIONARY WEIGHT LOSS AID WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONIST AND SECRETAGOGUES NOVEL GIP (GLUCOSE-DEPENDENT ISNULINOTROPIC POLYPEPTIDE) RECEPTOR AGONIST 180 TABLETS DIETARY SUPPLEMENT

Original FDA recall reason

Unapproved Drug Claims and Misbranded.

Recall details

Recall number
H-0593-2025
Event ID
97373
FDA status
Terminated
Initiated
Aug 6, 2025
Reported
Sep 24, 2025
Classified
Sep 12, 2025
Terminated
Feb 19, 2026
Quantity
85,950 units total
Location
Norcross, GA, United States
Initiation type
Voluntary: Firm initiated
Notification
Letter

Where it was distributed

Product was shipped to the following states: AL, AR, AZ, CA, CO, CT, DE, FL, GA, GU, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, PR, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV & WY.

FDA source record · H-0593-2025

Data updated September 16, 2026. View official FDA data ↗

Follow official FDA and manufacturer guidance.